Clinical Trial Update: Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab with AC chemotherapy in brain metastases from driven gene-negative non-squamous non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• AC
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-squamous Non-small-cell Lung Cancer, Brain Metastases | Phase 2 | Status: UNKNOWN